|Bid||0.00 x 800|
|Ask||0.00 x 2200|
|Day's Range||87.83 - 87.93|
|52 Week Range||8.80 - 87.93|
|Beta (5Y Monthly)||2.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 28, 2020 - Nov 02, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||75.62|
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to get cautious towards the current bull run since March and hedging or reducing many of their long positions. Some fund managers are betting on Dow hitting […]
Gilead Sciences said Friday it had completed its $21 billion acquisition of cancer treatment specialist Immunomedics. The two companies announced the acquisition last month in which Gilead agreed to pay $88 a share for Immunomedics. Gilead completed the tender offer for all outstanding shares of Immunomedics' shares on Friday.
Gilead Sciences got FDA approval for its Covid-19 treatment that already had emergency authorization, sending GILD stock up after hours on the day shares had touched a low.